SEGMENT REPORTING (Tables)

12 Months Ended

Dec. 31, 2022

SEGMENT REPORTING

Schedule of revenue by reportable segments

	Year Ended December 31,
(in thousands)	2022		2021		2020
Net Revenues
Generics, Established Brands, and Other	$	274,698	$	216,136	$	208,475

Rare Disease		41,687		—		—
Total net revenues	$	316,385	$	216,136	$	208,475
Segment earnings/(loss) before interest, taxes, depreciation and amortization (“EBITDA”) and reconciliation to (loss)/income before income taxes
Generics, Established Brands, and Other		78,958		63,418		78,790
Rare Disease		(18,348)		(18,571)		(15,620)
Depreciation and amortization		(56,973)		(47,252)		(44,638)
Corporate and other unallocated expenses(1)		(38,920)		(37,388)		(34,548)
Total operating loss	$	(35,283)	$	(39,793)	$	(16,016)
Interest expense, net		(28,052)		(11,922)		(9,452)
Other income/(expense), net		670		(4,343)		(494)
Loss before benefit for income taxes		(62,665)		(56,058)		(25,962)

(1) Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our consolidated statement of operations.

Schedule of revenue by geographic operations

(in thousands)	Years Ended December 31,
Location of Operations	2022		2021		2020
United States	$	312,427	$	211,893	$	202,881
Canada		3,958		4,243		5,594
Total Revenue	$	316,385	$	216,136	$	208,475

Schedule of property and equipment by geographic location

(in thousands)	December 31, 2022		December 31, 2021
United States	$	40,343	$	38,564
Canada(1)		1,856		13,831
India		1,047		276
Total property and equipment, net	$	43,246	$	52,671

⁽¹⁾Amounts as of December 31, 2022 exclude the land and building at our Canada facility, which are classified as held for sale as of December 31, 2022. These assets have a carrying value of $8.0 million.